The potential of saliva as an accessible and sensitive sample type for the detection of respiratory pathogens and host immunity.

Autor:	Laxton CS; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA., Peno C; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA., Hahn AM; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA., Allicock OM; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA., Perniciaro S; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA., Wyllie AL; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA. Electronic address: anne.wyllie@yale.edu.
Jazyk:	angličtina
Zdroj:	The Lancet. Microbe [Lancet Microbe] 2023 Oct; Vol. 4 (10), pp. e837-e850. Date of Electronic Publication: 2023 Jul 26.
DOI:	10.1016/S2666-5247(23)00135-0
Abstrakt:	Despite its prominence in early scientific records, the usefulness of saliva as a respiratory specimen has been de-emphasised over the past century. However, due to its low cost and reliance on specific supply chains and the non-invasive nature of its collection, its benefits over swab-based specimens are again becoming increasingly recognised. These benefits were highlighted over the course of the COVID-19 pandemic, where saliva emerged as a more practical, clinically non-inferior sample type for the detection of SARS-CoV-2 and saw numerous saliva-based diagnostic tests approved for clinical use. Looking forward, as saliva uniquely contains both respiratory secretions and immunological components, it has potentially wide applications, ranging from clinical diagnostics to post-vaccine disease burden and immunity surveillance. This Personal View seeks to summarise the existing evidence for the use of saliva in detecting respiratory pathogens, beyond SARS-CoV-2, as well as detailing methodological factors that can influence sample quality and thus, clinical utility. Competing Interests: Declaration of interests SP has received consulting or travel fees from Pfizer, Inventprise, Global Diagnostic Systems, and Vaxcyte, and is the Principal Investigator on a grant from Merck to Yale University, for work not related to this Personal View. ALW has received consulting or advisory board fees from Pfizer, RADx, Diasorin, PPS Health, Co-Diagnostics, Filtration Group, and Global Diagnostics Systems for work not related to this Personal View. ALW is a Principal Investigator for research grants funded by Pfizer, Merck, Flambeau Diagnostics, Tempus Labs, and The Rockefeller Foundation to Yale University. All other authors declare no competing interests. (Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu